QV FLARE UP BATH OIL

Product Information

Registration Status: Active

QV FLARE UP BATH OIL is approved to be sold in Singapore with effective from 2001-03-19. It is marketed by EGO PHARMACEUTICALS (SINGAPORE) PTE LTD, with the registration number of SIN11468P.

This product contains Benzalkonium Chloride 6% w/w,Light Liquid Paraffin 55.8% w/w, and Triclosan 2% w/w in the form of LOTION. It is approved for TOPICAL use.

This product is manufactured by EGO PHARMACEUTICALS PTY LTD in AUSTRALIA.

It is an Over-the-counter Medicine that can be freely obtained from any retailer

Benzalkonium Chloride
Light Liquid Paraffin
Triclosan


Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.


Active Ingredient/Synonyms

Drakeol 5 | Light Liquid Paraffin | Light Liquid Petrolatum | Light White Mineral Oil | Mineral Oil Light | Mineral Oil, High Viscosity | Mineral Oil, Light | Paraffin, Light Liquid | Paraffinum Perliquidum | Light Mineral Oil |


Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.


Description

An aromatic ether that is phenol which is substituted at C-5 by a chloro group and at C-2 by a 2,4-dichlorophenoxy group. It is widely used as a preservative and antimicrobial agent in personal care products such as soaps, skin creams, toothpaste and deodorants as well as in household items such as plastic chopping boards, sports equipment and shoes. [ChEBI]

Indication

Triclosan is used in a variety of common household products, including soaps, mouthwashes, dish detergents, toothpastes, deodorants, and hand sanitizers. It is also used in health care settings in surgical scrubs and personnel hand washes.

Mechanism of Action

At in-use concentrations, triclosan acts as a biocide, with multiple cytoplasmic and membrane targets. At lower concentrations, however, triclosan appears bacteriostatic and is seen to target bacteria mainly by inhibiting fatty acid synthesis. Triclosan binds to bacterial enoyl-acyl carrier protein reductase enzyme (ENR), which is encoded by the gene FabI. This binding increases the enzyme's affinity for nicotinamide adenine dinucleotide (NAD+). This results in the formation of a stable ternary complex of ENR-NAD+-triclosan, which is unable to participate in fatty acid synthesis. Fatty acids are necessary for reproducing and building cell membranes. Humans do not have an ENR enzyme, and thus are not affected.

Pharmacokinetics

Absorption
A study conducted in 2000 demonstrated that low amounts of triclosan can be absorbed through skin and can enter the bloodstream. [PMID: 10722890] Triclosan is rapidly absorbed and distributed in the human body (Sandborgh-Englund et al., 2006). Maximum concentrations are reached within three hours after oral intake. However, the metabolism and excretion of the compound is fast.
Distribution
Metabolism
Triclosan is prone to phase II metabolism via sulfotransferase and glucuronosyltransferase enzymes (Wang et al., 2004). In humans the resulting conjugates are excreted primarily in urine (Sandborgh-Englund et al., 2006).
Elimination

Toxicity

Oral LD50, Rat: 3700 mg/kg; Dermal LD50, Rabbit: 9300 mg/kg

Active Ingredient/Synonyms

2,4,4'-Trichloro-2'-hydroxydiphenyl ether | 5-Chloro-2-(2,4-dichloro-phenoxy)-phenol | Triclosan | Triclosanum | Triclosan |


Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.

References

  1. Health Science Authority of Singapore - Reclassified POM
  2. Drugbank